- HPLC tested for purity and identity
- Lot-matched certificate of analysis
- Ships next business day, tracked
Metabolic & Circadian Compounds
SR9009 (Stenabolic)
Synthetic Rev-Erb nuclear receptor agonist studied in circadian and metabolic models
- Mol. weight437.94 g/mol
- Research areasCircadian gene expression, mitochondrial biogenesis, lipid and glucose handling, macrophage inflammatory signalling
Overview
SR9009, widely known by the research label Stenabolic, is not a peptide. It is a synthetic small molecule developed as an agonist of the Rev-Erb nuclear receptors, REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These heme-binding receptors act as transcriptional repressors within the core circadian clock, linking the timing machinery of the cell to genes governing lipid and glucose metabolism, mitochondrial biogenesis and inflammatory signalling.
Its research profile stems from a set of rodent studies in which Rev-Erb agonism altered metabolic parameters and mitochondrial gene expression, producing the popular but imprecise description of an exercise mimetic. The published pharmacology carries important caveats: SR9009 shows poor oral bioavailability in reported mouse pharmacokinetics, and later work has argued that some of its cellular effects occur independently of Rev-Erb receptors, meaning target attribution cannot be assumed from phenotype alone.
SR9009 is not an approved drug in any jurisdiction, is not a dietary supplement, and is prohibited in sport by the World Anti-Doping Agency under the hormone and metabolic modulator category. Peptide Medix supplies it as 10 mg capsules in bottles of 60 and as a 30 mL liquid at 20 mg/mL, HPLC tested with a lot-matched certificate of analysis.
Specifications
Identity
- CAS number
- 1379686-30-2
- Molecular formula
- C20H24ClN3O4S
- Molecular weight
- 437.94 g/mol
Supply & purity
- Purity
- HPLC tested for purity and identity; lot-matched COA available
Additional detail
- Compound class
- Synthetic small molecule; nuclear receptor (Rev-Erb) agonist — not a peptide
- Molecular targets
- REV-ERBα (NR1D1) and REV-ERBβ (NR1D2)
- Also known as
- Stenabolic, SR-9009
- Available formats
- 10 mg × 60 capsules; 30 mL solution at 20 mg/mL
- Mechanistic role
- Enhances Rev-Erb transcriptional repression within the core circadian feedback loop
- Research areas
- Circadian gene expression, mitochondrial biogenesis, lipid and glucose handling, macrophage inflammatory signalling
- Reported pharmacokinetics
- Low oral bioavailability and short half-life reported in mouse studies
- Regulatory status
- Not approved as a medicine; not a dietary supplement; WADA-prohibited in sport
- Storage
- Cool, dry, dark; solution refrigerated and tightly capped
Units and conversions
Capsule and troche strengths are stated per unit, so the figure a method needs is usually a conversion rather than a dilution. The mcg to mg converter handles the milligram-to-microgram step, and the millilitre arithmetic if you are working from a solution format instead.
Certificate of analysis
Every lot of SR9009 (Stenabolic) is released against a certificate of analysis: the batch-specific laboratory data for that lot, not a generic document for the compound. The lot number on the certificate matches the lot number printed on the label you receive — the vial label itself, where the product is vialled — so the record and the material it describes can always be reconciled.
Purity: HPLC tested for purity and identity — the specification for this listing. The figure for the lot you receive is the one reported on that lot’s certificate.
No lot certificate is on display on this page at the moment. That is a publishing state and not a testing one: lots are released and documented as described above whether or not the document is posted here, and we will send what exists for the lot in stock, or for a lot already on your bench, by its number.
Certificates are available on request before you order as well as after, with no account and no charge. Request the certificate for this listing, read the testing and documentation policy in full, or see how to read a peptide COA.
Questions about SR9009 (Stenabolic)
Is SR9009 a peptide or a SARM?
Neither. SR9009 is a synthetic small molecule that acts on the Rev-Erb nuclear receptors, which are circadian clock components. SARMs target the androgen receptor, and peptides are amino acid chains. SR9009 belongs to the metabolic modulator category rather than either of those.
What is the concern about off-target activity?
Published work found that SR9009 retained cellular activity in cells lacking both Rev-Erb receptors, which means at least some of its effects are not mediated by its nominal target. Experiments should include genetic controls rather than assuming that any observed change reflects Rev-Erb engagement.
Which format should a laboratory choose?
The 20 mg/mL liquid is easier to dilute accurately for in-vitro work, since volumes can be measured directly. The 10 mg capsules suit study designs that require a fixed unit format. The compound itself is identical between the two.
Related
